EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness

Safia Kuriakose iD, Alice Tseng iD, Sarita Boyd, Sara Gibbons, Justin Chiong iD, Fiona Marra iD, Alison Boyle iD, Tessa Senneker iD, Jomy George, Claire Lund iD, Pamela Belperio iD, Page Crew iD und 6 weitere

Clinical Infectious Diseases · 17.03.2026 · 82 (3) · e446-e454

DOI: 10.1093/cid/ciaf606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.11.2025. Verfasst von Safia Kuriakose und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In December 2021 and January 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug, nirmatrelvir/ritonavir, was authorized in the United States, Canada, and Europe. However, ritonavir has significant drug-drug interaction (DDI) potential, and information resources were incomplete or provided conflicting advice for certain DDIs. Within the challenging pandemic setting, nirmatrelvir/ritonavir was being prescribed largely by clinicians unfamiliar with ritonavir. Coronavirus disease 2019 (COVID-19) affects people with comorbid conditions and polypharmacy who could benefit from therapy, but prescriber uncertainty surrounding the appropriate management of DDIs was a barrier to the use of nirmatrelvir/ritonavir. To support clinicians, the National Institutes of Health (NIH) panel on COVID-19 guidelines, the Ontario COVID-19 Science Advisory Table, and the University of Liverpool independently developed prescribing guidelines. Ultimately, the groups united to establish the LiON-PK (Liverpool-Ontario-NIH Pharmacokinetics) collaboration. Here we describe how the team developed pragmatic and harmonized guidance for managing DDIs with nirmatrelvir/ritonavir. This framework may inform development of prescribing resources for other complex medications or for future pandemic preparedness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsHumansDrug InteractionsSARS-CoV-2United StatesInternational CooperationCOVID-19Practice Guidelines as TopicPandemic PreparednessLactamsLeucineNitrilesProline

Stichwörter der Autor:innen

COVID-19drug interactionsinternational collaborationnirmatrelvir/ritonavirpandemic

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Toronto General Hospital, University Health Network and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
  • Division of Antivirals, Office of Infectious Diseases, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Centre for Experimental Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Infection and Immunology Clinic, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
  • Health, People and Human Services Group, ICF, Reston, Virginia, USA.

ORCID-Profile: Safia Kuriakose, Alice Tseng, Justin Chiong, Fiona Marra, Alison Boyle, Tessa Senneker, Claire Lund, Pamela Belperio, Page Crew, Greg Eschenauer, Kimberly K Scarsi, Catia Marzolini

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Kuriakose, S., Tseng, A., Boyd, S., Gibbons, S., Chiong, J., Marra, F., Boyle, A., Senneker, T., George, J., Lund, C., Belperio, P., Crew, P., Eschenauer, G., Scarsi, K. K., Khoo, S. H., Pau, A., Marzolini, C., & LiON-PK collaboration (2026). International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. Clinical Infectious Diseases, 82(3), e446-e454. https://doi.org/10.1093/cid/ciaf606

Vancouver

Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, et al. International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. Clinical Infectious Diseases. 2026;82(3):e446-e454. doi:10.1093/cid/ciaf606

BibTeX
@article{Kuriakose2026,
  author = {Kuriakose, Safia and Tseng, Alice and Boyd, Sarita and Gibbons, Sara and Chiong, Justin and Marra, Fiona and Boyle, Alison and Senneker, Tessa and George, Jomy and Lund, Claire and Belperio, Pamela and Crew, Page and Eschenauer, Greg and Scarsi, Kimberly K and Khoo, Saye H and Pau, Alice and Marzolini, Catia and LiON-PK collaboration, LiON-PK collaboration},
  title = {International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {3},
  pages = {e446--e454},
  doi = {10.1093/cid/ciaf606}
}
Kostenlos starten →